CAR-T cell therapy in less than 2 year old children with infant acute
lymphoblastic leukemia : case reports and review of the literature
Abstract
Infant acute lymphoblastic leukemia (infant ALL) is known for its poor
prognosis. Current treatment protocols include aggressive chemotherapy
and allogeneic stem cell transplantation but prognosis remains poor.
Immunotherapy is a new approach with promising results. CAR-T cell
therapy has recently been approved for relapsed or refractory childhood
ALL but lacks documentation regarding infant ALL. We describe here two
cases of patients suffering from infant ALL who were treated with CAR-T
cell therapy, the feasibility and efficiency of treatment and their
outcome.